Dexcom (DXCM) Director Eric Topol Sells 20,000 Shares

Dexcom (NASDAQ:DXCM) Director Eric Topol sold 20,000 shares of the stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $100.10, for a total transaction of $2,002,000.00. Following the transaction, the director now directly owns 3,695 shares in the company, valued at approximately $369,869.50. The transaction was disclosed in a filing with the SEC, which is available through this link.

NASDAQ DXCM traded down $0.41 during trading hours on Thursday, hitting $98.41. The company’s stock had a trading volume of 71,348 shares, compared to its average volume of 1,195,784. Dexcom has a 52 week low of $42.62 and a 52 week high of $101.50. The stock has a market cap of $8.37 billion, a price-to-earnings ratio of -172.48 and a beta of -0.01. The company has a debt-to-equity ratio of 0.79, a quick ratio of 5.42 and a current ratio of 5.83.

Dexcom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.32). Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The business had revenue of $184.40 million for the quarter, compared to analysts’ expectations of $172.66 million. During the same quarter last year, the firm earned ($0.49) EPS. The firm’s revenue for the quarter was up 29.6% compared to the same quarter last year. sell-side analysts predict that Dexcom will post -0.51 EPS for the current year.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Dexcom from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. BMO Capital Markets raised shares of Dexcom to an “outperform” rating and set a $78.00 price objective on the stock in a research report on Thursday, March 29th. Piper Jaffray Companies set a $80.00 price objective on shares of Dexcom and gave the stock a “buy” rating in a research report on Thursday, March 29th. JPMorgan Chase & Co. raised shares of Dexcom from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $80.00 to $115.00 in a research report on Friday, June 8th. Finally, Canaccord Genuity increased their price objective on shares of Dexcom from $81.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 3rd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Dexcom presently has a consensus rating of “Buy” and an average target price of $74.50.

Large investors have recently bought and sold shares of the business. FDx Advisors Inc. increased its stake in Dexcom by 33.3% in the 4th quarter. FDx Advisors Inc. now owns 23,071 shares of the medical device company’s stock valued at $1,324,000 after buying an additional 5,764 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Dexcom by 8.9% in the 1st quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock valued at $191,943,000 after buying an additional 211,250 shares during the last quarter. California Public Employees Retirement System increased its stake in Dexcom by 3.8% in the 4th quarter. California Public Employees Retirement System now owns 134,300 shares of the medical device company’s stock valued at $7,707,000 after buying an additional 4,900 shares during the last quarter. Geode Capital Management LLC increased its stake in Dexcom by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 800,783 shares of the medical device company’s stock valued at $45,956,000 after buying an additional 8,444 shares during the last quarter. Finally, American International Group Inc. purchased a new stake in Dexcom in the 4th quarter valued at about $116,000.

Dexcom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Insider Buying and Selling by Quarter for Dexcom (NASDAQ:DXCM)

Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply